Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Opdivo

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Opdivo was produced by Gilead Sciences.

HTA guidance from NICE, the SMC and the AWMSG

NICE concluded that obesity caused by. 15 Jul 2022. Within the final appraisal document (FAD), NICE also recommended extending the guidance of Opdivo plus Yervoy to treat rarer forms of mesothelioma ... The treatment is also under review by. 8 Jul 2022.

Bristol Myers Squibb announces NICE recommendation for Opdivo plus Yervoy to treat unresectable malignant pleural mesothelioma

Bristol Myers Squibb announces NICE recommendation for Opdivo plus Yervoy to treat unresectable malignant pleural mesothelioma Patients treated with Opdivo plus Yervoy lived a median of four months longer than those who received chemotherapy alone. ... Within the final appraisal document (FAD), NICE also recommended extending the guidance of Opdivo plus Yervoy to treat rarer

Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment

Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment The National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) to treat adult patients with muscle invasive urothelial carcinoma (MIUC). ... NICE’s decision was supported by results from

FDA approves BMS’ Opdivo with chemotherapy for certain lung cancer patients

FDA approves BMS’ Opdivo with chemotherapy for certain lung cancer patients Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for use in combination with chemotherapy every three weeks for three cycles. ... The trial compared Opdivo plus chemotherapy to

BMS’ Opdivo improves survival in early-stage lung cancer

BMS’ Opdivo improves survival in early-stage lung cancer Pre-surgical Opdivo improves survival in non-small cell lung cancer patients, reinforcing its efficacy in early-stage cancers. ... Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that harnesses the body’s immune system to fight tumours

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Innovative Trials

Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...